Evidence of Genomic Damage Induced By Prodigiosin Produced By Serratia Marcenscens Ufpeda 395 in Human Peripheral Blood Mononuclear Cells

Introduction

Prodigiosin is synthesized by a number of microorganisms, such as Serratia marcescens. This compound represents the newest family of antitumor drugs and causes immunosuppression as well as the selective blocking of T lymphocytes, B lymphocytes and natural killer cells Montaner et al. [1,2]. Prodigiosin is a red pigment from the alkaloid class with a linear-chain tripyrrole structure (pyrrole, 3 methoxypyrrole, 2-methyl-3-amylpyrrole) Guryanov et al. [3] Like a number of secondary bacterial metabolites, prodigiosin has acquired practical importance in recent years. Beyond its pharmaceutical applications, this pigment has been employed industrially for dying methacrylate products, polymethylene and paper Mapari et al. [4-7] and has also been used in diverse methods for the acquisition of petroleum-based products Silva et al.

Prodigiosin is known to induce apoptosis in a variety of human cancer cells, with little toxicity to normal cells. This characteristic gives prodigiosin a huge advantage as an anti-cancer agent Pandey et al. [8,9]. The induction of DNA cleavage is among the mechanisms of action attributed to this compound Pérez-Tomás et al. [9]. Due to the growing use of prodigiosin as a pharmaceutical product (Sigma-Aldrich, CAS Number, 56144-17-3) and accumulating knowledge on its action as a potential anti-cancer agent Hsieh et al. [10], studies are needed to clarify its likely mechanisms of action to determine the best forms of administration. This need is based on the few data available on the selective action of prodigiosin in normal cells with regard to genomic damage. The aim of the present study was to investigate possible genomic damage induced by prodigiosin in normal human mononuclear cells through genotoxicity tests.

Material and Methods

Acquisition of Prodigiosin

Prodigiosin was obtained from the cultivation of Serratia marcescens UFPEDA 398. The pigment was purified using thinlayer chromatography, identified by UV-visible spectrometry in the 200 to 700 nm range and characterized using gas chromatographymass spectrometry based on the methods described by Nakashima et al. [11].

Sample Collection

Lymphocytes were obtained from human peripheral blood. The sample size was calculated based on 10 healthy individuals (5 men and 5 women between 20 and 50 years of age). The exclusion criteria for the participants were drug use, medication use, cardiovascular disease, cancer, hypertension and other adverse health conditions. This study received approval from the Human Research Ethics Committee of the Center for Health Sciences of the Federal University of Pernambuco (Brazil) under process number: 18177413.4.0000.5208. Approximately 5mL of peripheral venous blood were collected from each individual using a sterile heparinized syringe for use in all treatments. The samples were duly labeled for subsequent processing Neves.

Sample Processing

After blood collection, the syringes were left in the vertical position for two hours to allow the sedimentation of the cells. Three layers were formed due to density differentiation: two layers of cells and a layer of plasma. For the isolation of the cells, the plasma from each sample was discarded and 1mL of the cell layer containing lymphocytes (layer with a milky appearance) was transferred to a 5mL test tube containing RPMI 1640 medium (Cultilab) with phytohemagglutinine. The cells were then incubated for 48 hours at 37oC Mooreheat et al. [12]. For the comet assay, approximately 15μl of cell suspension were homogenized in 100μl of low-meltingpoint agar. After incubation, 1mL of prodigiosin was added to the cultures at different concentrations (0.5, 1.0, 10 and 100μM/mL) and the samples were incubated for an additional 24 hours at 37 oC.

The positive and negative controls were doxorubicin (at the same concentrations as prodigiosin) and the culture medium without the addition of any agents, respectively. Following incubation, the samples were transferred to centrifuge tubes and submitted to centrifugation at 1500 rpm for 6 minutes. The culture medium was then discarded and the cells were re-suspended in 1mL of phosphate buffered saline (PH 7.4). Two drops of cell suspension were transferred to previously washed, wet slides. The slides were left to dry in horizontal position at room temperature and then fixed with absolute methanol (P.A.) for 5 minutes. After rinsing in running water, the slides were stained with Giemsa stain (Merck), which was deposited uniformly and left to react for 5 minutes. The slides were once again rinsed in running water and left to dry at room temperature. The comet assay was used for the evaluation of genomic damage, following the method described by Singh et al. [13].

Approximately 15μL of cell suspension were homogenized in 100μL of low-melting-point agar previously heated to 37oC in a water bath. The homogenate was then transferred to glass slides coated with standard agarose, covered with cover slips and incubated for 10 min at 4oC. The cover slips were removed and the slides were immersed in a lysis solution for two hours at 4oC, followed by electrophoresis (40 V for 20 minutes and 300 mA). The slides were then immersed in a neutralization solution for 15 minutes and fixed with an absolute ethanol solution for 5 minutes. After drying, the slides were stored under refrigeration until staining. For such, Gel Red (Biotarget GelRed®) (1μL) was homogenized in 1000μL of sterile de-ionized water (1:1000). After staining, the slides were analyzed with fluorescence microscopy (Olympus, BX Series) for the determination of the cell counts. According to Tice et al. [13], approximately 100 cells per individual were analyzed, with nucleoid damage scored from 0 (no damage, intact nucleus and missing comet tail), 1 (damage inicial, little nuclear fragmentation and small comet tail formation), 2 (moderate nuclear fragmentation and observation of comet tail formation), 3 (intense nuclear fragmentation, small nucleus materials preseverd and observation of a comet tail and prolonged) and 4 (intense nuclear fragmentation, almost no nuclear materials preserved and observation of a comet tail and prolonged).

Data Analysis

Micronucleated cells were analyzed under an optical microscope (Olympus BX 60) with an immersion objective. Approximately 1000 cells per individual were analyzed for the quantification of micronucleated cells. Cells with one or more micronuclei were included in the analysis. Bartlett’s test of equal variance was used in the comparison of the samples. ANOVA was used for the comparison of samples with equal variance and the Kruskal-Wallis test was used for samples with unequal variance. Tukey’s post hoc test was used for the confirmation of the results. The same tests were used in the comparison of cells from male and female individuals. The level of significance set to 5% (p < 0.05) for all statistical tests.

Results

The formation of micronuclei occurred following exposure to the different concentrations of prodigiosin (Table 1) and (Figure 1). The pigment exhibited statistically significant genotoxic effects in all treatments (Figure 2). A direct relationship was found between the frequency of micronuclei and concentration of prodigiosin, with the largest mean number of micronuclei (62.6) found following exposure to the highest concentration of the pigment (100μM/mL) (Table 1). This proportional increase in comparison to the negative control was evidenced with both prodigiosin and doxorubicin, with relative constancy found in the proportionality among the concentrations of these two substances (Table 2). Apoptotic cells were also found with the highest concentration of prodigiosina (100μM/mL) (Figure 3) but were not quantified in the present study.

Figure 1: Presence of micronuclei in lymphocytes from human peripheral blood after 24 hours of exposure to different concentrations of prodigiosin; A1-A3: negative control (cells without micronuclei); B1-B3: micronuclei in cells exposed to 0.5.

Figure 2: Apoptotic lymphocyte after 24 hours of exposure at concentration of 100μM/mL.

Figure 3: Results of Kruskal-Wallis test for comparisons of frequencies of micro nucleated cells following exposure to different concentrations of prodigiosin and doxorubicin.

Table 1: Absolute and mean number of micronucleated cells following exposure to different concentrations of (μM/mL) of prodigiosin and doxorubicin.

Note: *Positive control.

Table 2: Proportionality index of mean number of micronucleated cells in different treatments.

Note: **Positive control.

The Kruskal-Wallis test revealed statistically significant differences in comparison to the negative control regarding the frequency of micronucleated cells following exposure to the different concentrations of the substances. No significant differences were found between prodigiosin and the positive control, except at the concentration of 0.5μM/mL (Figure 3). These findings were confirmed by Tukey’s post hoc test (Table 3). The comet assay revealed statistically significant differences in comparison to the negative control regarding genomic damage at prodigiosin concentrations of 1.0, 10.0 and 100.0 μM/mL (Table 4) and (Figure 4). The ANOVA findings were confirmed by Tukey’s post hoc test (Table 5). No significant differences were found regarding the frequency of micronucleated cells or genomic damage in the comparison of cells from males and females (Figures 5-7) and (Table 6).

Table 3: Results of Tukey’s post hoc test for the comparison of frequencies of micronucleated cells following exposure to different concentrations (μM/mL) of prodigiosin and doxorubicin.

Note: Non-significant values in bold type.

Statistical significance: p < 0.05.

Table 4: Damage indices following exposure to different concentrations (μM/mL) of prodigiosin.

Table 5: Results of Tukey’s post hoc test in comparison of damage indices following exposure to different concentrations (μM/mL) of prodigiosin.

Note: Non-significant values in bold type.

Table 6: Results of Tukey’s post hoc test for the comparison between sexes regarding frequencies of micronucleated cells and damage indices following exposure to different concentrations (μM/mL) of prodigiosin.

Note: Non-significant values in bold type.

Figure 4: Results of ANOVA in comparison of damage indices in lymphocytes following exposure to different concentrations of prodigiosin.

Figure 5: Results of ANOVA for comparisons between sexes of frequencies of micro nucleated cells following exposure to different concentrations of prodigiosin.

Figure 6: Results of ANOVA for comparisons between sexes of damage to lymphocytes following exposure to different concentrations of prodigiosin.

Figure 7: Genomic damage observed in normal human peripheral mononuclear blood cells after treatment with different concentrations of prodigiosin (0.5, 1.0, 10.0 and 100.0 mM / ml) of 48h.

Discussion

Prodigiosin is considered a promising anti-cancer agent due to its mechanisms of action and selective toxicity, affecting only cancer cells Pérez-Tomáz et al. [14-16]. However, the present findings indicate a considerable effect on normal cells, as evidenced by the high number of micronucleated cells and significant damage index (comet assay) at all concentrations tested on normal lymphocytes. The genotoxic effect of prodigiosin demonstrated a dose-dependent relationship, as a greater frequency of micronucleated cells occurred at the highest concentrations tested (Table 1), regardless of the sex of the volunteers from which the cells were taken (Table 6) and (Figures 5 & 6). This relationship was also demonstrated by the proportionality indices (Table 2). The expression of micronuclei was fourfold greater at the lowest concentration of prodigiosin tested (0.5μM/mL) and 26-fold greater at the highest concentration (100.0μM/mL). It was observed that the prodigiosin induced genomic damage in cells from the lower concentration 0.5μM/mL whereas this concentration increases obviously observed a more intense level of damage. Therefore, it can be stated concentrations equal or above 10μM/mL induce significant damage grade 2 and 3 (Figure 7).

Both prodigiosin and the positive control (doxorubicin) demonstrated considerable genomic damage to the lymphocytes, with doxorubicin exhibiting a greater effect in comparison to prodigiosin when the drugs were used at a concentration of 0.5μM/ mL, as evidenced by the results of Tukey’s post hoc test (Table 3) and the mean values displayed in (Table 1). The similarity in the dose-dependent effect of these drugs is likely due to their structural similarity. Both prodigiosin and doxorubicin are DNA intercalating agents. Due to their planar chemical structure, these molecules are capable of interacting with the DNA molecule and affecting its stability Montaner et al. [14]. Four mechanisms are considered regarding the action of prodigiosin as an anti-cancer agent:

a. The induction of intracellular acidification;

b. The induction of DNA cleavage through the inhibition of topoisomerase I and II;

c. The modulation of MAPK activity; and

d. The inhibition of the progression of the cell cycle Perez- Tomás et al. [9-10].

Among these mechanisms of action, the first three can lead to the induction of apoptosis Soto Cerrato et al. [17]. Regarding the mechanism related to DNA cleavage, Montaner et al. [15] report that the binding of prodigiosin to the double strand inhibits the action of topoisomerase I and II, transforming these essential enzymes into lethal DNA-damaging agents (Turner and Denny, 1996; Montaner et al. [18-19,15]. Prodigiosin fixes enzyme-DNA cleavage complexes, resulting in breaks in the DNA molecule Montaner et al. [15]. These DNA fragments may give rise to micronuclei during cell division, as suggested by the findings of the present study (Figure 1). This fragmentation can also been seen in the significant differences in the damage indices among the different concentrations of prodigiosin tested in relation to the negative control (Tables 4 & 5) (Figure 4). Damage to the double strand of DNA as a consequence of the inhibition of topoisomerase by prodigiosin is dependent on the processing of chromatin related to the apoptotic process induced by the drug Campás et al. [1,15,9]. This independent relationship of the two effects of prodigiosin was evidenced in the present study. Apoptotic cells (Figure 2) were only found following exposure to 100.0μM/mL of the pigment, whereas genomic damage was found after exposure to all concentrations tested (Tables 1 & 4). The presence of apoptotic cells at the highest concentration is in partial agreement with data reported by Soto Cerrato et al. [17], who found that low, non-cytotoxic concentrations of prodigiosin cause blocking of the cell cycle and high concentrations induce apoptosis. (The suppression of the cell cycle was not evaluated in the present study.) Moreover, the genomic damage found at all concentrations likely stems from the induction of oxidative damage to DNA by prodigiosin Melvin et al. [20,21].

Few data have been published on the genotoxic effects of prodigiosin, especially on normal cells, which underscores the biotechnological innovation of the present investigation. Larazo et al. [22] found no significant mutagenic or genotoxic effects of prodigiosin with regard to micronucleus counts in Salmonella typhimuriun or L51718y lymphocytes obtained from lymphomas in rats using the Ames test. Guryanov et al. [3] also found no significant genotoxic effects of this pigment on Salmonella typhimuriun and peripheral red blood cells from mice. However, it describes the mutagenic potential of prodigiosin evidenced by Ames test. In contrast, Cavalcanti et al. [23], states that prodigiosin induces toxic effect decreasing cell viability when treated at lower concentrations of 0.6 to 4.8μM/mL as the highestthe. These data corroborate those found in present study substantial genotoxic effects on normal lymphocytes, as both evaluation methods employed demonstrated significant clastogenicity. As prodigiosin can cause breaks in both DNA strands and such damage is more difficult for the cell to repair Montaner et al. [15], cells submitted to this drug can become compromised due to the induction of apoptosis and the harmful effects of genomic damage.

The therapeutic potential of prodigiosin in the treatment of cancer is widely recognized in the medical-scientific community, mainly due to its direct action on DNA, leading to the suppression of the cell cycle and apoptosis of cancer cells Hsieh et al. [10,16]. However, the genotoxic effects found in the present study suggest non-selective action, with effects on normal cells as well. Therefore, further studies on the effects of this drug should be carried out on different normal cells lines for the confirmation of the non-selective genotoxic effects of prodigiosin to ensure greater efficiency and the minimization of risks regarding the use of this drug.

Conclusion

Prodigiosin exhibited significant genotoxic effects on normal human lymphocytes exposed to different concentrations of this pigment for 24 hours. These effects were evidenced by an increase in the frequency of micronuclei and genomic damage to the cells analyzed.

Study the Nephroprotective Effect of Ziziphus jujube Extract Against Cisplatin -Induced Nephrotoxicity-https://biomedres01.blogspot.com/2021/01/study-nephroprotective-effect-of.html